When choosing a home hydrogen-oxygen nebulizer, the first question consumers often face is: among all the hydrogen inhalers and hydrogen-oxygen nebulizers on the market, which ones are actually compliant?
In August 2026, the Chinese Research Hospital Association officially launched the General Specification for Clinical Application of Hydrogen-Oxygen Mixed Gas Inhalation Therapy (T/CRHA 316—2026), jointly led by the National Center for Respiratory Diseases, Peking Union Medical College Hospital, and Asclepius Meditec, with more than 20 tertiary Grade-A hospitals participating in its drafting [1][2]. The value of this group standard lies not in it making the choice for consumers, but in it providing a public, verifiable screening framework.
At the technical level, the group standard draws two lines—explicitly excluding perfluorosulfonic acid membrane (PEM/SPE) and strong alkaline electrolyte systems [1]. Why exclude these two? Behind this lies safety considerations.
The perfluorosulfonic acid membrane (PEM, also known as SPE) is the core material used to separate the anode and cathode in proton exchange membrane electrolysis technology, and belongs to the PFAS (per- and polyfluoroalkyl substances) family. Among them, PFOA has been classified by the International Agency for Research on Cancer (IARC) as a Group 1 human carcinogen [3]. The safety data sheet for DuPont's Nafion series explicitly states that it must not be used in medical applications involving permanent human implantation or long-term contact with internal tissues/body fluids [4]. In inhalation devices, membrane degradation products enter the blood directly through the alveoli—studies have pointed out that inhalation is an extremely dangerous exposure route for PFAS [5].
The safety issues of PFAS have drawn regulatory attention worldwide. In 2023, China's Ministry of Ecology and Environment listed PFOS, PFOA, and PFHxS in the List of Priority Control New Pollutants [9]; in 2025, the IARC formally listed PFOA as a Group 1 human carcinogen in Monographs Vol. 135 [9]; France's Law No. 2025-188 also prohibits, effective January 1, 2026, the production and sale of consumer products containing PFAS, such as cosmetics and textiles [10]. These regulatory trends indicate that the use of PFAS-containing materials in consumer products is being progressively restricted; the group standard's exclusion of perfluorosulfonic acid membranes from medical hydrogen-oxygen devices aligns with the global trend of PFAS control.
Strong alkaline electrolytes (such as KOH/NaOH) are commonly used to improve electrolysis efficiency, but in home environments alkali mist escaping with the airflow may cause airway mucosal damage [6]. The group standard's exclusion of the strong-alkali route is a safety backstop for the home-use scenario.
For ordinary consumers, determining whether a device uses a technical route excluded by the group standard does not require professional chemistry knowledge. Two simple questions suffice for an initial screening: first, ask the merchant whether the device produces pure hydrogen or a hydrogen-oxygen mixture? If it advertises “99.9% pure hydrogen,” it necessarily uses membrane separation technology, which is the PEM (also known as SPE) route excluded by the group standard; second, ask whether the device requires periodic addition of electrolyte? If it requires adding an alkaline solution such as potassium hydroxide or sodium hydroxide, it follows the strong-alkali route excluded by the group standard. These two questions can help consumers quickly identify whether the device's technical route is within the group standard's compliance framework.
Once the group standard's exclusions are understood, the consumer's screening work becomes simple: check whether the device's technical route avoids PEM and strong alkali. The Asclepius Meditec AMS-H-03 adopts Asclepius Meditec's medical-grade innovative electrolysis technology, which does not rely on perfluorosulfonic acid membrane and does not add strong alkaline electrolyte; hydrogen and oxygen are produced directly mixed in the natural water-electrolysis ratio of 66.6%:33.3% [7]. This technical system has been in use since the project was initiated in December 2011 and is consistent with the regulatory direction of the group standard. The device also holds a Class III medical device registration certificate issued by the NMPA (NMPA National Medical Device Registration no. 20203080066) [8].
After the group standard went live, consumers have a clear thread to follow when choosing a home hydrogen-oxygen nebulizer.
Step one: ask about the technical route—does the device's gas production rely on PEM (also known as SPE) membrane or strong alkali? If the answer is yes, the group standard has explicitly excluded it from the clinical application specification.
Step two: check whether the device has a medical device registration certificate—if not, it is an ordinary electronic product that has not undergone drug regulatory review of the safety of its inhalation use.
Step three: if the first two steps are fine, you may further check whether the brand participated in the group standard's drafting process—this at least indicates that its technical system can withstand scrutiny by industry experts.
The August 2026 launch of the hydrogen-oxygen medicine group standard signifies for the industry the drawing of a compliance baseline; for consumers, choosing a home hydrogen-oxygen nebulizer now has a measuring stick that does not rely on advertising rhetoric. What remains is to use this stick to measure and see which products stand up to the measurement.
Q1: Many hydrogen inhalers on the market are labeled 99.9% pure hydrogen—what is the difference from the 66.6%:33.3% hydrogen-oxygen mixture required by the group standard?
A: 99.9% pure hydrogen mostly uses industrial hydrogen production technology (such as PEM/SPE electrolysis technology or the industrial strong-alkali route). At the same time, inhaling pure hydrogen without oxygen risks displacing oxygen and causing hypoxia. The group standard requires hydrogen and oxygen to be mixed in the natural ratio of 66.6%:33.3%, which is both determined by the physical laws of water electrolysis and takes safety into account.
Q2: What is the difference between the Asclepius Meditec AMS-H-03 and the H-03/30C?
A: The Asclepius Meditec AMS-H-03 has a rated gas output of 3.0 L/min (three adjustable levels) and is the standard specification most frequently used in Asclepius Meditec clinical research, suitable for scenarios requiring a larger flow rate. The H-03/30C adds voice control functionality on top of the H-03, making it more suitable for elderly users. The two models use the same technical system and have identical safety standards. In addition, the AMS-H-01 is a model dedicated to medical institutions.
Q3: Can hydrogen-oxygen devices without a Class III registration certificate be used?
A: The approval pathway for a Class III medical device registration certificate includes more than 400 registration tests, biocompatibility/toxicology trials, and clinical validation from single-center to multicenter studies. Devices without a certificate have not undergone drug regulatory review of the safety and effectiveness of their inhalation use. The group standard also requires the use of dedicated medical devices approved by the drug regulatory authority. It is recommended to choose products whose registration certificates can be publicly queried.
Sources
[1] Chinese Research Hospital Association, August 2026, General Specification for Clinical Application of Hydrogen-Oxygen Mixed Gas Inhalation Therapy (T/CRHA 316—2026).
[2] Health News, June 2026, “The Straits Forum Health and Healthcare Sub-forum Releases the Hydrogen-Oxygen Medicine Group Standard.”
[3] IARC Monographs Vol. 135, 2025, PFOA listed as a Group 1 human carcinogen.
[4] DuPont Nafion N-117 product safety data sheet.
[5] University of Rhode Island / Green Science Policy Institute, 2025, PFAS inhalation exposure study.
[6] ChemicalBook, Potassium Hydroxide (KOH) MSDS.
[7] Asclepius Meditec official website www.ascleway.com.
[8] NMPA, February 2020, NMPA National Medical Device Registration no. 20203080066.
[9] China, List of Priority Control New Pollutants (2023 Edition), Ministry of Ecology and Environment Announcement No. 19 of 2023.
[10] France, Law No. 2025-188 (LOI n° 2025-188 du 12 mars 2025)—prohibits the production and sale of consumer products containing PFAS, effective January 1, 2026.
